Because the prognosis of patients with rapid recurrence is extremely poor, and their immune status are unique, these DEGs are very likely to become the first potential targets or biomarkers other than PD-L1 for immunotherapy in early-stage lung cancer in the future. This evidence concerns the gene CD274 and lung cancer.